We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Novellus

News List

Novellus Licenses Induced Mesenchymal Stem Cells to NoveCite for COVID-19 Related ARDS americanpharmaceuticalreview
October 19, 2020
Novellus Therapeutics has licensed its induced mesenchymal stem cells (iMSCs) on a worldwide basis to NoveCite, a newly formed subsidiary of Citius Pharmaceuticals.
Citius licences Novellus’ stem cell therapy for Covid-19-related ARDS pharmaceutical-technology
April 03, 2020
Citius Pharmaceuticals has entered an exclusive six-month option agreement to licence a stem cell therapy from Novellus to treat acute respiratory distress syndrome (ARDS) related to Covid-19 infection.
Citius, Novellus Ink COVID-19 Pact contractpharma
April 02, 2020
Citius to license novel stem-cell therapy for acute respiratory distress syndrome (ARDS) associated with COVID-19.